BPI-16350 explained

Legal Status:	Investigational
Pubchem:	135181567
Synonyms:	BPI16350
Iupac Name:	N-[5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-''a'']benzimidazol-8-yl)pyrimidin-2-amine
C:	28
H:	32
F:	2
N:	8

BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer.^{[1] [2]} It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.^[3]

Notes and References

1. Gao . Shuiping . Liu . Ru-Jiao . Chen . Yang . Wang . Yi-qian . Chen . Hong . Zhang . Hui-juan . Ma . Tian-yi . Wang . Jia-bing . Hu . Xi-Chun . Zhang . Jian . A novel potent CDK4/6 inhibitor BPI-16350 in preclinical cancer models . 28 March 2022 . 10.21203/rs.3.rs-1333630/v1.
2. Ray-Coquard . Isabelle . Monk . Bradley J. . Lorusso . Domenica . Mahdi . Haider . Upadhyay . Vivek . Graul . Regina . Husain . Amreen . Mirza . Mansoor Raza . Slomovitz . Brian . The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma . International Journal of Gynecologic Cancer . 31 October 2023 . 33 . 12 . 1943–1949 . 10.1136/ijgc-2023-004739 . 37907262 . 264844023 . en . 1048-891X. free . 10804003 .
3. Zhang . Jian . Liu . Rujiao . Gao . Shuiping . Chen . Wenyan . Han . Xinghua . Ma . Yanjie . Ding . Lieming . Wang . Jiabing . Lan . Hong . Hu . Xichun . BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study. . Journal of Clinical Oncology . 1 June 2023 . 41 . 16_suppl . e13051 . 10.1200/JCO.2023.41.16_suppl.e13051. 259083530 .